Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Guam for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Guam only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Guam (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Samir Ambrale (NPI 1780990382)

Field	Value
Entity Type	Individual
Organization	Samir Ambrale
Address	548 Marine Corps Dr
City	Tamuning
State	GU
ZIP	96913
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 20, 2010

Payer Source	Total Paid
Medicare	$292.3K
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician whose Medicare billing is heavily centered on injectable cancer-related therapies and office E/M visits, with the single largest revenue driver being denosumab (J0897) followed by routine E/Ms (99213) and chemotherapy administration (96413). The top 3 Medicare codes by revenue account for 73.8% of the provider's total Medicare revenue, indicating a concentrated service mix focused on a few high-volume/high-revenue items.

Revenue concentration is notable: J0897 alone represents $166.3K (57.7% of Medicare revenue) and, together with 99213 ($23.8K) and 96413 ($22.5K), these three codes produce the bulk of the $292.3K lifetime Medicare revenue reported for this NPI. This concentration suggests the practice’s financial performance is closely tied to access and prescribing/administration of a small set of oncology therapeutics.

Payer mix is effectively single-payer: the profile shows Total Medicare revenue of $292.3K and no Medicaid billing on file, so the provider operates without a recorded Medicaid footprint and is dependent on Medicare as the primary public payer. For analysts, this means Medicaid trends or state program shifts are unlikely to directly affect this provider unless future billing patterns change.

Competitive standing on the leading drug code is mid-range nationally: J0897 ranks #1297 of 10057 providers (87th percentile), which the source labels as typical and unremarkable volume relative to peers — the provider is neither a national outlier nor a low-volume user of denosumab but does have above-average placement. By contrast, office E/M code 99213 is in the 90th percentile nationally (#46862 of 457151), indicating comparatively strong use of routine office visits versus peers.

Chemotherapy administration and supportive oncology services show typical volumes across multiple codes: 96413 ranks #3099 of 7514 (59th percentile) and add-on infusion codes (96417, 96415) sit around typical-to-below-typical percentiles. This pattern is consistent with a community oncology practice that delivers outpatient IV/subcutaneous cancer therapies and associated short office visits rather than a high-throughput infusion center or academic referral center.

Code-level anomalies in the top-25 list are limited to items with zero reported payment amounts despite high claim counts (for example, J1100, J1453, J2405 show many claims with $0 avg paid/claim). These entries are reported as $0 revenue in the supplied data and should prompt a claims-level review if reconciliation or contract-payment differences are of interest, but they do not contribute to reported Medicare revenue totals.

Provider tenure is long-standing: NPI was enumerated on 2010-08-20 (~16 years ago), indicating a sustained presence in Medicare billing and suggesting established referral relationships and clinical continuity in the local market. This longevity supports the interpretation that the observed code mix reflects stable practice patterns rather than a transient or recently changed service line.

Operational implications: the heavy revenue reliance on a single high-cost injectable (J0897) creates sensitivity to drug acquisition, reimbursement policy changes, and utilization management for denosumab. Payer or policy shifts that affect coverage, unit pricing, or preferred agents could disproportionately affect this provider’s Medicare revenue given the 57.7% share from that one code.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	9,240	$20	$166.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	360	$70	$23.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	190	$120	$22.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	160	$130	$21.5K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	2,460	$10	$14.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	140	$80	$10.4K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	50	$120	$5.5K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	80	$60	$4.5K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	250	$10	$3.2K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	250	$10	$2.9K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Guam Distribution

Samir Ambrale — 3 of 16 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Guam

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0897	1	10	9,240	$20	$170.2K
99214	48	90	140	$90	$25.7K
J9217	1	10	160	$130	$21.5K
96413	2	10	190	$110	$20.6K
Q5106	1	10	2,460	$10	$13.8K
99213	14	100	100	$60	$10.6K
99204	20	50	30	$110	$6.7K
96417	2	10	120	$60	$6.7K
96415	2	10	220	$20	$5.3K
96375	2	10	250	$10	$4.3K

Showing 1–10 of 19

Nearby Providers

Other providers in the same ZIP code as Samir Ambrale, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Lee	GU	Dentist	$0	$10.9M
Guam Memorial Hospital	GU	General Acute Care Hospital	$0	$3.5M
Rsa - Tumon, LLC	GU	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$2.9M
Robert Yang	GU	Dentist	$0	$2.4M
Antonio Garcia	GU	Pediatrics Physician	$0	$2.2M
Ma Gladys Linsangan	GU	Pediatrics Physician	$0	$2.2M
Ari Katerelos	GU	Radiation Oncology Physician	$2.1M	$0
Guam X-ray	GU	Vascular & Interventional Radiology Physician	$0	$2.1M
Sarah Clegg	GU	General Practice Dentistry	$0	$1.7M
Peter Kh Go	GU	Surgery Physician	$152.8K	$1.5M

Samir Ambrale — Billing Profile & Reimbursement Data

Sign up for Samir Ambrale — Billing Profile & Reimbursement Data policy alerts

Samir Ambrale — Billing Profile & Reimbursement Data

Sign up for Samir Ambrale — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References